Question: Based on the Women’s Health Initiative (WHI) sub‑analysis, hormone therapy is most likely to be safest for which of the following patients?

Answer Choices:\n\nA. 73-year-old woman 21 years beyond menopause B. 58-year-old woman 4 years beyond menopause C. 56-year-old woman 12 years beyond menopause D. 62-year-old woman 8 years beyond menopause

Answer:B

 

Question: Which osteoporosis treatment is approved only for postmenopausal women at high risk of fracture and is limited to 2 years of use?

Answer Choices:\n\nA. Raloxifene B. Denosumab C. Alendronate D. Teriparatide

Answer:D. Teriparatide

 

Question: Which osteoporosis medication has a boxed warning for potential increased risk of osteosarcoma?

Answer Choices:\n\nA. Denosumab (Prolia®) B. Raloxifene (Evista®) C. Teriparatide (Forteo®) D. Alendronate (Fosamax®)

Answer:C. Teriparatide (Forteo®)

 

Question: Which of the following are cautions/reasons to avoid Veozah® (fezolinetant)? (Select ALL)

Answer Choices:\n\nA. May worsen depression B. Contraindicated with CYP1A2 inhibitors C. Consider risk of VTE/other CV events D. Do not use if eGFR <30 mL/min E. Hepatic function tests required at baseline & during therapy

Answer:B, D, E

 

Question: The primary purpose of administering bazedoxifene as a component of hormone therapy in menopause is to:

Answer Choices:\n\nA. Increase the efficacy of estrogenic activity in breast tissue B. Minimize the occurrence of tissue specific adverse effects associated with estrogen therapy C. Act as an estrogen agonist in endometrial tissue D. Minimize the occurrence of tissue specific adverse effects associated with progestin therapy

Answer:B

 

Question: A spike in which hormone(s) is/are responsible for promoting ovulation?

Answer Choices:\n\nA. Follicle stimulating hormone (FSH) B. Luteinizing hormone (LH) C. Progesterone D. Inhibin

Answer:A and B

 

Question: Which of the following best describes the FDA “Pregnancy and Lactation Labeling Rule” (PLLR)?

Answer Choices:\n\nA. Implementation of a standardized rating system for lactation safety B. Updated FDA pregnancy letter categories for more precise risk info C. Reorganization of pregnancy & lactation info in product labeling, adding a reproductive risk/safety section D. Standardization of risk info in labeling and tertiary resources

Answer:C

 

Question: A primary care provider wants to start estrogen in a postmenopausal woman. Which strategy is most appropriate to minimize risks?

Answer Choices:\n\nA. Use the lowest dose for the shortest duration necessary B. Highest dose, discontinue at age 65 C. Standard dose indefinitely D. An appropriate dose, duration, regimen, and route

Answer:D

 

Question: What would a woman experience if she had normal prolactin levels, but no oxytocin?

Answer Choices:\n\nA. No milk production, but normal milk ejection B. Normal milk production and normal milk ejection C. No milk production and no milk ejection D. Normal milk production, but no milk ejection

Answer:D

 

Question: A 21-year-old woman on TriNessa® complains of increased acne and weight gain. Most appropriate recommendation?

Answer Choices:\n\nA. Change to a COC with decreased progestin & androgen activity B. Change to a COC with increased progestin & androgen activity C. Change to a COC with increased progestin activity D. Change to a COC with decreased androgen activity E. No change; wait to see if complaints resolve

Answer:D

 

Question: Which of the following is NOT a common side effect of letrozole?

Answer Choices:\n\nA. Neutropenia B. Hypercholesterolemia C. Menopause-like symptoms (hot flashes, etc.) D. Arthralgia/myalgia

Answer:A

 

Question: Which osteoporosis therapy is contraindicated in patients with a history of venous thromboembolism (VTE)?

Answer Choices:\n\nA. Raloxifene (Evista®) B. Alendronate (Fosamax®) C. Teriparatide (Forteo®) D. Denosumab (Prolia®)

Answer:A. Raloxifene (Evista®)

 

Question: What is a serious but rare adverse effect associated with bisphosphonates such as alendronate?

Answer Choices:\n\nA. Hypoglycemia B. Osteonecrosis of the jaw C. Pulmonary fibrosis D. Seizures

Answer:B. Osteonecrosis of the jaw

 

Question: SC is a 47 year old postmenopausal female with familial history of breast cancer. Which agents are appropriate for risk reduction? (Select ALL)

Answer Choices:\n\nA. Fulvestrant (Faslodex®) B. Raloxifene (Evista®) C. Tamoxifen (Nolvadex®) D. Epirubicin (Ellence®)

Answer:B and C

 

Question: When treating symptoms of menopause, a progestogen is generally administered in order to offer:

Answer Choices:\n\nA. Protection of the endometrium B. Protection from breast cancer C. Protection of the ovaries D. Protection from osteoporosis

Answer:A

 

Question: Both acute and dose‑related chronic cardiotoxicity are adverse effects most commonly associated with:

Answer Choices:\n\nA. Cyclophosphamide B. Capecitabine (Xeloda®) C. Paclitaxel (Taxol®) D. Doxorubicin (Adriamycin®)

Answer:D

 

Question: Which of the following drugs is known to stimulate bone formation rather than inhibit bone resorption?

Answer Choices:\n\nA. Alendronate B. Raloxifene C. Denosumab D. Abaloparatide

Answer:D. Abaloparatide